Clinical Trials Logo
  1. Home
  2. Pancreatic Cancer Resectable
  3. NCT05483257

Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma

Pancreatic Cancer Resectable Clinical Trial

Official title:
Molecular Subtyping Based on Specific HLA-I Genotypes for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma: A Retrospective Observational Cohort Study

Clinical Trial Summary

Pancreatic adenocarcinoma (PAAD) patients following surgeries are prone to relapse shortly, while it is not well understood by current biomarkers. Given the potential associations of human leukocyte antigen class I (HLA-I) genotype with oncogenic mutational profile and immunotherapy efficacy, we aimed to assess whether differential HLA-I genotype could predict the postoperative outcomes in resected PAAD patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05483257
Study type Observational
Source Ruijin Hospital
Contact
Status Completed
Phase
Start date March 14, 2018
Completion date September 13, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06368063 - The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer Phase 4
Not yet recruiting NCT06375928 - EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease (CARPEDIEM-1 Trial) N/A
Recruiting NCT06388967 - Pancreatic Cancer Detection Consortium
Recruiting NCT05287165 - Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms Early Phase 1
Not yet recruiting NCT06287749 - French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
Recruiting NCT03977233 - Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer Phase 2
Recruiting NCT04736043 - Development of a Prediction Platform for Adjuvant Treatment and Prognosis in Resected Pancreatic Cancer Using Organoid
Completed NCT04224402 - Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients. Phase 2
Terminated NCT03344172 - Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer Phase 2
Not yet recruiting NCT05479708 - ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
Not yet recruiting NCT05637567 - Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head Phase 2
Recruiting NCT05181605 - Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors Phase 2/Phase 3